Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: A subanalysis of the FIN-RACO trial

Annals of the Rheumatic Diseases

Volumn 73, Issue 4, 2014, Pages 788-790

  Rantalaiho, Vappu ^a   Kautiainen, Hannu ^b,c,d   Korpela, Markku ^a   Puolakka, Kari ^e   Blåfield, Harri ^f   Ilva, Kirsti ^g   Hannonen, Pekka ^h   Leirisalo Repo, Marjatta ^b,c   Möttönen, Timo ^d  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e SOUTH KARELIA CENTRAL HOSPITAL   (Finland)

^f SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^g Hameenlinna Central Hospital   (Finland)

^h JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; PREDNISOLONE;

DISEASE ACTIVITY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; WORK DISABILITY;

DMARDS (SYNTHETIC); EARLY RHEUMATOID ARTHRITIS; OUTCOMES RESEARCH; RHEUMATOID ARTHRITIS; TREATMENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG MONITORING; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; PREDNISOLONE; REMISSION INDUCTION;

EID: 84895502537     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204271     Document Type: Letter

References (10)

1. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9. (Pubitemid 38942816)
2. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis-MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010;69:1789-95.
3. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
4. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;156:329-39.
5. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18. (Pubitemid 27351112)
6. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73. (Pubitemid 29219206)
7. Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011;70:1039-46.
8. Leirisalo-Repo M, Kautiainen H, Laasonen L, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis 2013;72:851-7.
9. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
10. Puolakka K, Kautiainen H, Möttönen T, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36-41. (Pubitemid 40129230)